Research on the Radiotoxicology of Plutonium Using Animals: Consideration of the 3Rs—Replace, Reduce, Refine

Abstract To characterize the health effects of incorporated plutonium, many experiments have been conducted using different animal models. These range from (1) applied (tissue uptake/retention determination, decorporation therapy efficacy), (2) fundamental (gene expression, cancer induction), and (3) dosimetry models. In recent years, the use of animals for scientific purposes has become a public concern. The application of the 3Rs - Replace (use of alternative methods or animals not considered capable of experiencing pain, suffering, and distress), Reduce (reduction in animal numbers), and Refine (better animal welfare and minimization of suffering, pain and distress) - has increased to address ethical concerns and legislative requirements. The introduction of novel non-animal technologies is also an important factor as complementary options to animal experimentation. In radiotoxicology research, it seems there is a natural tendency to Replace given the possibility of data reuse obtained from contamination cases in man and animal studies. The creation of “registries” and “repositories” for nuclear industry workers (civil and military) is now a rich legacy for radiotoxicological measurements. Similarly, Reduction in animal numbers can be achieved by good experimental planning with prior statistical analyses of animal numbers required to obtain robust data. Multiple measurements in the same animal over time (external body counting, excreta collection) with appropriate detection instruments also allow Reduction. In terms of Refinement, this has become “de rigueur” and a necessity given the societal and legal concerns for animal welfare. For research in radiotoxicology, particularly long-term studies, better housing conditions within the constraints of radiation protection issues for research workers are an important concern. These are all pertinent considerations for the 3Rs remit and future research in radiotoxicology.

[1]  W. Russell,et al.  Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.

[2]  P. Bérard,et al.  Treatment of actinide exposures: a review of Ca-DTPA injections inside CEA-COGEMA plants. , 2007, Radiation protection dosimetry.

[3]  B. Miller,et al.  Actinide bioimaging in tissues: Comparison of emulsion and solid track autoradiography techniques with the iQID camera , 2017, PloS one.

[4]  M. Graham,et al.  The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease , 2015, European journal of pharmacology.

[5]  A. Khademhosseini,et al.  Bioengineering the Lung : Molecules , Materials , Matrix , Morphology , and Mechanics Computational and bioengineered lungs as alternatives to whole animal , isolated organ , and cell-based lung models , 2012 .

[6]  Erin E. Jarvis,et al.  From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. , 2017, Chemico-biological interactions.

[7]  L. Miccoli,et al.  Chelation Treatment by Early Inhalation of Liquid Aerosol DTPA for Removing Plutonium after Rat Lung Contamination , 2019, Radiation Research.

[8]  R. Landes,et al.  Interval estimators of relative potency in toxicology and radiation countermeasure studies: comparing methods and experimental designs , 2018, Journal of biopharmaceutical statistics.

[9]  A. Ryan (Firth),et al.  Application of iPSC to Modelling of Respiratory Diseases , 2021, Advances in experimental medicine and biology.

[10]  Yi Wang,et al.  Is there a role for the adverse outcome pathway framework to support radiation protection? , 2018, International journal of radiation biology.

[11]  Qasim Chaudhry,et al.  Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities? , 2017, Regulatory toxicology and pharmacology : RTP.

[12]  J. Angulo,et al.  A quick and simple in vitro assay to predict bioavailability of actinides following accidental exposure. , 2019, Toxicology in vitro : an international journal published in association with BIBRA.

[13]  T. Miller,et al.  RELATIVE DISSOLUTION RATES OF RADIOACTIVE MATERIALS USED AT AWE. , 2016, Radiation protection dosimetry.

[14]  V. Khokhryakov,et al.  In vitro dissolution study of plutonium in aerosol particles from the Mayak PA: a tool for individualised dose estimates. , 2007, Radiation protection dosimetry.

[15]  B. Lai,et al.  An iron-dependent and transferrin-mediated cellular uptake pathway for plutonium. , 2011, Nature chemical biology.

[16]  M. Festing.  On determining sample size in experiments involving laboratory animals , 2018, Laboratory animals.

[17]  N. Griffiths,et al.  Exploiting the “ Rat Actinide Repository “ at the Laboratory of RadioToxicology, CEA, France , 2019, BIO Web of Conferences.

[18]  J. Angulo,et al.  Forecasting the In Vivo Behavior of Radiocontaminants of Unknown Physicochemical Properties Using a Simple In Vitro Test , 2016, Health physics.

[19]  H. Métivier,et al.  Design of a new inhalation device for rodents and primates , 1989 .

[20]  J. F. Park,et al.  Overview of Biological Consequences of Exposure to Plutonium and Higher Actinides , 1989 .

[21]  J. Angulo,et al.  In vitro assessment of plutonium uptake and release using the human macrophage-like THP-1 cells. , 2016, Toxicology in vitro : an international journal published in association with BIBRA.

[22]  J. Everitt,et al.  Recommendations for Addressing Harm–Benefit Analysis and Implementation in Ethical Evaluation – Report from the AALAS–FELASA Working Group on Harm–Benefit Analysis – Part 2 , 2016, Laboratory animals.

[23]  C. Loffredo,et al.  The Russian Human Radiobiological Tissue Repository: A Unique Resource for Studies of Plutonium-Exposed Workers , 2017, Radiation Protection Dosimetry.

[24]  Soile Tapio,et al.  Big data in radiation biology and epidemiology; an overview of the historical and contemporary landscape of data and biomaterial archives , 2019, International journal of radiation biology.

[25]  Icrp.  Human Respiratory Tract Model for Radiological Protection , 1994 .

[26]  S. Lam,et al.  Macrophages, Inflammation, and Lung Cancer. , 2016, American journal of respiratory and critical care medicine.

[27]  J. Poncy,et al.  Activation of Alveolar Macrophages after Plutonium Oxide Inhalation in Rats: Involvement in the Early Inflammatory Response , 2008, Radiation research.

[28]  C. L. Sanders,et al.  Phagocytosis of Inhaled Plutonium Oxide-239Pu Particles by Pulmonary Macrophages , 1968, Science.

[29]  Alia Zander,et al.  Radiation databases and archives – examples and comparisons , 2019, International journal of radiation biology.

[30]  R. Ewing,et al.  Long-term storage of spent nuclear fuel. , 2015, Nature materials.

[31]  Lynne U. Sneddon,et al.  Considering aspects of the 3Rs principles within experimental animal biology , 2017, Journal of Experimental Biology.

[32]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[33]  A M Brues.  Plutonium--health implications for man. The use of animal data in derivation of standards. , 1975, Health physics.

[34]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[35]  R. Kathren.  A review of contributions of human tissue studies to biokinetics, bioeffects and dosimetry of plutonium in man. , 2004, Radiation protection dosimetry.

[36]  Thomas C. Ferrante,et al.  Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro , 2015, Nature Methods.

[37]  G. Lumetta,et al.  Review of the Scientific Understanding of Radioactive Waste at the U.S. DOE Hanford Site. , 2018, Environmental science & technology.

[38]  J. Evans,et al.  The distribution of dust in the rat lung following administration by inhalation and by single intratracheal instillation. , 1985, Environmental research.

[39]  R. Mittal,et al.  Organ‐on‐chip models: Implications in drug discovery and clinical applications , 2018, Journal of cellular physiology.

[40]  M. Greiner,et al.  Refining animal research: The Animal Study Registry , 2019, PLoS biology.

[41]  P. Durbin.  LAURISTON S. TAYLOR LECTURE: THE QUEST FOR THERAPEUTIC ACTINIDE CHELATORS , 2008, Health physics.

[42]  Jiwang Chen,et al.  Alveolar type I cells protect rat lung epithelium from oxidative injury , 2006, The Journal of physiology.

[43]  K. Unger,et al.  Independent Validation of Candidate Genes Identified after a Whole Genome Screening on Mayak Workers Exposed to Prolonged Occupational Radiation , 2014, Radiation research.

[44]  Daniel L Villeneuve,et al.  Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.

[45]  Elliot Lilley,et al.  PREPARE: guidelines for planning animal research and testing , 2017, Laboratory animals.

[46]  A. F. Eidson,et al.  In vitro dissolution of respirable aerosols of industrial uranium and plutonium mixed-oxide nuclear fuels. , 1983, Health physics.

[47]  Ahmad M Khalil,et al.  Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens. , 2014, Lung cancer.